CIK 0000715446
- Non-accelerated filer
- Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 112622630
- Phone
- +1 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 4 Open-market buy Director bought 210,000 shares at $0.11 ($23,835)
- 4 Open-market buy Director bought 54,958 shares at $0.15 ($8,139)
- 4 Open-market buy Director bought 175,000 shares at an average $0.16 ($27,262)
- 4/A Open-market buy Director bought 100,000 shares at an average $0.15 ($14,725)
- 4 Open-market buy President and CEO bought 80,000 shares at an average $0.15 ($11,824)
- 4 Open-market buy Director bought 100,000 shares at an average $0.15 ($14,725)
- 4 Open-market buy Director bought 15,000 shares at $0.13 ($1,901)
- 4 Open-market buy Director bought 280,000 shares at an average $0.13 ($37,796)
- 4 Open-market buy Director bought 150,000 shares at an average $0.14 ($20,920)
- 4 Open-market buy President and CEO bought 130,000 shares at an average $0.13 ($17,310)
- 4 Open-market buy Director bought 50,000 shares at $0.15 ($7,500)
- 4 Open-market buy Director bought 25,000 shares at $0.14 ($3,450)
- 4 Open-market buy President and CEO bought 25,000 shares at $0.14 ($3,558)
- 4 Open-market buy Director bought 150,000 shares at an average $0.14 ($21,720)
- 4 Open-market buy President and CEO bought 20,000 shares at an average $0.14 ($2,848)
- 4 Open-market buy Director bought 42,000 shares at $0.14 ($5,922)
- 4 Open-market buy Director bought 36,000 shares at $0.14 ($5,040)
- 4 Open-market buy Director bought 136,025 shares at $0.16 ($21,220)
- 4 Open-market buy President and CEO bought 20,000 shares at $0.16 ($3,250)
- 4 Open-market buy Director bought 25,000 shares at $0.16 ($4,000)
Page 15 of 24 · 471 filings